Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 07 Jan 2025 for EyePoint Pharmaceuticals, Inc.. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
John B. Landis: trading record in brief
John B. Landis (board member) discloses dealings in EyePoint, Inc. to SEC (Form 4). Between 9 February 2022 and 5 January 2025, the trades on record add up to 3 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 7 January 2025, reports an option exercise in EyePoint, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to John B. Landis
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
10,000 shares0Common StockSEC:0001562180-25-000227:0
3,000 shares0Common StockSEC:0001562180-23-001335:0
2,500 shares0Common StockSEC:0001562180-22-001420:0
3 of 3 declarations
